Miranova (Ethinylestradiol, Levonorgestrel)

The formulation contains ethinylestradiol, a synthetic estrogen, and levonorgestrel, a progestin. Together they suppress the mid‑cycle surge of luteinizing hormone (LH) and follicle‑stimulating hormone (FSH), preventing ovulation, thickening cervical mucus, and altering the endometrial lining to inhibit implantation.

The specific dosing regimen for Miranova is determined by a qualified prescriber. Typically, a combined oral contraceptive is taken as one tablet daily at the same time each day, but the exact schedule and any missed‑dose instructions must be provided by the healthcare professional.

Miranova is not intended for use during pregnancy and should be discontinued if pregnancy occurs. While limited data exist for breastfeeding, most guidelines advise caution; the prescriber will assess the risk‑benefit ratio for nursing mothers before recommending use.

To order Miranova, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Miranova contains the standard dose combination of ethinylestradiol and levonorgestrel, which is widely used and well‑studied. Compared with newer progestin‑only pills or extended‑cycle regimens, Miranova offers a conventional 21‑day active‑tablet schedule with a predictable hormonal profile, making it familiar to many clinicians and patients.

Miranova tablets should be stored at ambient temperature, below 25 °C, in their original blister pack or container. Protect them from excess moisture and direct sunlight. Do not store in the bathroom or near heat sources, and keep out of reach of children.

Miranova is taken orally, usually as one tablet each day. It is recommended to start the first tablet on the first day of the menstrual period or within the first five days of the cycle. Consistent daily intake at the same time helps maintain efficacy.

Serious but rare risks include venous thromboembolism, pulmonary embolism, stroke, myocardial infarction, severe hypertension, and liver tumors. Women with a history of clotting disorders, smoking over age 35, or certain cardiovascular conditions should be evaluated carefully before use.

Miranova is contraindicated in women with known or suspected pregnancy, active or history of thromboembolic disease, uncontrolled hypertension, certain liver diseases, hormone‑dependent cancers, or those who are smokers over 35 years old. A thorough medical history is essential to identify any contraindications.